USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: CRYOLIFE, INC.
City: KENNESAW
State: GA
Zip+4: 30144
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (770) 419-3355

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $885,096.00 14
SBIR Phase II $2,059,077.00 4

Award List:

CRYOPRESERVATION OF VENOUS AND ARTERIAL TISSUE

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert t mcnally phd
Award Amount: $50,000.00
Abstract:
Currently in the united states there are 360,000 small vessel implants and 100,000 peripheral vascular reconstructions annually. of this population needing vascular surgery, approximately 15 percent of the patients do not have vessels suitable for autografts. a prototype procedure has been developed… More

CRYOPRESERVATION OF LIGAMENTS AND TENDONS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The worldwide potential market for ligament and tendon implants is in excess of 100,000 units annually. the currently available prosthetic implants are clinically unsatisfactory and autologous grafts may compromise the site of tissue origin. the long term objective of this project is to develop… More

DEVELOPMENT OF NOVEL CRYOPRESERVATION TECHNIQUE FOR HUMAN RED BLOOD CELLS

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency / Branch: DOD / NAVY
Principal Investigator: Dr John F Carpenter
Award Amount: $500,000.00
Abstract:
With current fda-approved protocols for the cryopreservation of human red blood cells, the cells are treated with multimolar concentrations of glycerol, a permeating cryoprotectant. after thawing, extensive processing of red cells is required to remove the glycerol, prior to transfusion, to prevent… More

DEVELOPMENT OF NOVEL CRYOPRESERVATION TECHNIQUE FOR HUMAN RED BLOOD CELLS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency / Branch: DOD / NAVY
Principal Investigator: Dr John F Carpenter
Award Amount: $48,125.00

REPOPULATION OF XENOGRAFT HEART VALVES WITH FIBROBLASTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brockbank, Kelvin G , Principal Investigator
Award Amount: $50,000.00
Abstract:
During the last 20 years, allograft heart valve transplantation in the united states has increased from about 50 to 2,000 per annum. because of this increased demand, particularly for pediatric cases, utilization of these cryopreserved heart valves is now limited by the supply of donated human… More

BONE MARROW CRYOPRESERVATION WITH ANTIFREEZE PEPTIDES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brockbank, Kelvin G , Principal Investigator
Award Amount: $49,285.00
Abstract:
This study focuses on the use of antifreeze peptides in the development of an improved method for cryopreservation of bone marrow progenitor cells. recombinant antifreeze peptides have been found to inhibit migratory recrystalization during thawing of erythrocytes and to permit reduction in… More

DEVELOPMENT OF A FIBRIN SEALANT DELIVERY METHOD

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Morse, Brenda S , Principal Investigator
Award Amount: $48,820.00

DEVELOPMENT OF A FIBRIN SEALANT DELIVERY METHOD

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Morse, Brenda S , Principal Investigator
Award Amount: $500,000.00
Abstract:
Fibrin sealant has many applications in surgery. mixing and delivery of the major components, fibrinogen and thrombin, is currently achieved using two syringes or spray containers dispensed alternately or simultaneously to deliver fibrin sealant onto the wound site. these systems of delivery are… More

Ultraviolet B Irradiation of Allogeneic Veins

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kelvin G. Brockbank
Award Amount: $50,000.00
Abstract:
The major factor limiting more widespread utilization of allogeneic veins in arterial bypass procedures is the recipients' immune response. The intimal endothelial cells appear to be the focus of this immune response, which results in loss of the intimal lining of the vessel lumen during the first… More

Xenograft Heart Valves--Biomechanics/Collagen Structure

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven Goldstein
Award Amount: $74,576.00
Abstract:
Though allograft human aortic valves are preferred for transplantation by virtue of their lowthrombogenicity and immunogenicity, superior hemodynamic performance, and extended durability, onlyabout 2,000 per year are implanted due to limited donated heart supply. An acellular porcine heart… More

Bioadhesive for Surgery and Wound Repair

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Brenda Morse
Award Amount: $99,782.00
Abstract:
We will develop a strong, safe, easy-to-use, biocompatible, and degradable bioadhesive for surgicalrequiring tissue sealing and closure. This bioadhesive will have the potential to streamline commonwell as provide new technology in areas such as organ hemostasis. The following specific aims will… More

Xenogeneic Arterial Bypass Graft

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven Goldstein
Award Amount: $73,360.00
Abstract:
Although the autogenous saphenous vein is the vessel typically utilized in arterial bypass procedurarise in which it is not possible to use this vein, demanding an alternative method. The investigatofeasibility study in canine subjects to determine whether an immunologically modified xenogeneic… More

Fascia Lata Xenograft for ACL Replacement

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven Goldstein
Award Amount: $91,680.00
Abstract:
Autologous patellar tendon grafts are the current gold standard for replacement of irreparable anteligaments. Allogeneic tissue grafts are the only accepted alternative to autologous grafts and theysupply. We will develop a non-immunogenic bovine fascia lata as a graft material for anterior… More

ENGINEERED HEART VALVE--FLOW AND FIBROBLAST FUNCTION

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,484.00

ENGINEERED HEART VALVE--FLOW AND FIBROBLAST FUNCTION

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $744,296.00

CRYOPRESERVED ARTERIES AS ALLOGRAFT VASCULAR CONDUIT

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ollerenshaw, jeremy d
Award Amount: $99,984.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jeremy D. Ollerenshaw
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jeremy D. Ollerenshaw
Award Amount: $314,781.00